146
Views
3
CrossRef citations to date
0
Altmetric
Short Report

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C

, , , , , , , , & show all
Pages 1115-1119 | Received 12 May 2012, Accepted 15 May 2012, Published online: 07 Jun 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Martin Lagging, Karolina Rembeck, Mads Rauning Buhl, Peer Christensen, Olav Dalgard, Martti Färkkilä, Kristoffer Hellstrand, Nina Langeland, Magnus Lindh, Johan Westin & Gunnar Norkrans. (2013) Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian Journal of Gastroenterology 48:7, pages 839-847.
Read now

Articles from other publishers (2)

Christina Sølund, Henrik Krarup, Santseharay Ramirez, Peter Thielsen, Birgit T. Røge, Suzanne Lunding, Toke S. Barfod, Lone G. Madsen, Britta Tarp, Peer B. Christensen, Jan Gerstoft, Alex L. Laursen, Jens Bukh & Nina Weis. (2014) Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations. PLoS ONE 9:12, pages e113034.
Crossref
María A Jiménez-Sousa, Amanda Fernández-Rodríguez, María Guzmán-Fulgencio, Mónica García-Álvarez & Salvador Resino. (2013) Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Medicine 11:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.